Tizona Therapeutics, Inc.
c/o MPM Capital
601 Gateway Blvd., Suite 350
South San Fransico
13 articles with Tizona Therapeutics, Inc.
9/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, today announced the appointment of Christine O’Brien as Chief Executive Officer, effective immediately
Gilead to Acquire 49.9% Equity Interest in Tizona – – Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments – – Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –
Tizona Therapeutics, Inc., a privately held, clinical stage company developing first-in-class cancer immunotherapies, announced that its Investigational New Drug application for TTX-080, a novel antibody targeting HLA-G, has been cleared by the U.S. Food and Drug Administration.
Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today that Scott Clarke, Chief Executive Officer, will present at The Cowen and Company 40th Annual Healthcare Conference on Wednesday, March 4th a
Tizona Announces Publication in Cancer Discovery Highlighting the Important Role of CD39 and Extracellular ATP in Inflammasome-driven Anti-Tumor Immunity
Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today the online publication of an article in Cancer Discovery describing novel mechanisms to more potently modulate the adenosine pathway and activate anti-tumor immune responses using antibodies that block CD39.
Tizona Therapeutics, Inc., a clinical stage, privately held immunotherapy company, today announced the appointment of Joyson Karakunnel, MD, MSc, FACP as Senior Vice President and Chief Medical Officer .
Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board of Directors.
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019
TTX-030 is the first anti-CD39 therapeutic to be studied in patients
Privately-held Tizona Therapeutics snagged $105 million in upfront cash as its cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.
AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Initiation of clinical studies with TTX-030 is targeted in Q1 2019